Cue Biopharma Inc. (CUE)
Cue Biopharma Statistics
Share Statistics
Cue Biopharma has 63.35M shares outstanding. The number of shares has increased by 30.23% in one year.
| Shares Outstanding | 63.35M |
| Shares Change (YoY) | 30.23% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 22.95% |
| Shares Floating | 62.87M |
| Failed to Deliver (FTD) Shares | 600 |
| FTD / Avg. Volume | 0.25% |
Short Selling Information
The latest short interest is 1.78M, so 2.81% of the outstanding shares have been sold short.
| Short Interest | 1.78M |
| Short % of Shares Out | 2.81% |
| Short % of Float | 2.83% |
| Short Ratio (days to cover) | 1.54 |
Valuation Ratios
The PE ratio is -1.51 and the forward PE ratio is -2.35. Cue Biopharma's PEG ratio is 0.04.
| PE Ratio | -1.51 |
| Forward PE | -2.35 |
| PS Ratio | 6.61 |
| Forward PS | 1 |
| PB Ratio | 3.51 |
| P/FCF Ratio | -1.69 |
| PEG Ratio | 0.04 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Cue Biopharma.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.84, with a Debt / Equity ratio of 0.51.
| Current Ratio | 1.84 |
| Quick Ratio | 1.84 |
| Debt / Equity | 0.51 |
| Debt / EBITDA | -0.21 |
| Debt / FCF | -0.24 |
| Interest Coverage | 52.14 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $175.23K |
| Profits Per Employee | $-767.43K |
| Employee Count | 53 |
| Asset Turnover | 0.29 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -40.67M |
| Effective Tax Rate | 100% |
Stock Price Statistics
The stock price has increased by -55.37% in the last 52 weeks. The beta is 1.88, so Cue Biopharma's price volatility has been higher than the market average.
| Beta | 1.88 |
| 52-Week Price Change | -55.37% |
| 50-Day Moving Average | 1.19 |
| 200-Day Moving Average | 1.08 |
| Relative Strength Index (RSI) | 28.85 |
| Average Volume (20 Days) | 241.17K |
Income Statement
In the last 12 months, Cue Biopharma had revenue of 9.29M and earned -40.67M in profits. Earnings per share was -0.72.
| Revenue | 9.29M |
| Gross Profit | 9.29M |
| Operating Income | -41.5M |
| Net Income | -40.67M |
| EBITDA | -41.5M |
| EBIT | -41.47M |
| Earnings Per Share (EPS) | -0.72 |
Balance Sheet
The company has 22.46M in cash and 8.88M in debt, giving a net cash position of 13.58M.
| Cash & Cash Equivalents | 22.46M |
| Total Debt | 8.88M |
| Net Cash | 13.58M |
| Retained Earnings | -341.86M |
| Total Assets | 44.81M |
| Working Capital | 20.47M |
Cash Flow
In the last 12 months, operating cash flow was -36.33M and capital expenditures -66K, giving a free cash flow of -36.4M.
| Operating Cash Flow | -36.33M |
| Capital Expenditures | -66K |
| Free Cash Flow | -36.4M |
| FCF Per Share | -0.65 |
Margins
Gross margin is 100%, with operating and profit margins of -446.86% and -437.97%.
| Gross Margin | 100% |
| Operating Margin | -446.86% |
| Pretax Margin | -437.97% |
| Profit Margin | -437.97% |
| EBITDA Margin | -446.86% |
| EBIT Margin | -446.86% |
| FCF Margin | -391.89% |
Dividends & Yields
CUE does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for CUE is $2.5, which is 216.5% higher than the current price. The consensus rating is "Buy".
| Price Target | $2.5 |
| Price Target Difference | 216.5% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
Scores
| Altman Z-Score | -11.04 |
| Piotroski F-Score | 4 |